The use of the new fixed-dose artesunate-mefloquine formulation ASMQ and the equivalent treatment consisting of the two drugs administered separately for the treatment of Plasmodium falciparum malaria in Thailand were studied (including monitoring of adverse effects). It was found that ASMQ was efficacious, safe, well tolerated and competitively priced, with a favourable pharmacokinetic profile, a simple regimen and a convenient coformulation, but that it could not be recommended in pregnancy or severe malaria, and caused cumulative toxicity with repeated dosing.
Presentatation from: Scientific Symposium "Implementation of Artemisinin Combination Therapies (ACTs): Role of ASMQ". Rio de Janeiro, Brazil, 17 April 2008.
FACT Project AS-MQ